(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 30.2% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 120.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Aquestive Therapeutics's revenue in 2025 is $44,132,000.On average, 12 Wall Street analysts forecast AQST's revenue for 2025 to be $4,575,320,374, with the lowest AQST revenue forecast at $3,941,676,397, and the highest AQST revenue forecast at $5,329,729,673.  On average, 12 Wall Street analysts forecast AQST's revenue for 2026 to be $6,926,504,516, with the lowest AQST revenue forecast at $5,081,916,440, and the highest AQST revenue forecast at $8,062,655,890.  
In 2027, AQST is forecast to generate $9,844,318,353 in revenue, with the lowest revenue forecast at $4,945,095,612 and the highest revenue forecast at $15,392,343,062.